Metastatic breast cancerBackground Outcome of HER2-positive metastatic breast cancer (MBC) patients has improved since the use of trastuzumab. However, most HER2-positive MBC patients will progress within 1 year of trastuzumab-based therapy. Only limited data are available concerning long-term ...
Conclusion: It could be shown that, compared to historical controls, targeted therapy against HER2 prolongs overall survival of patients with HER2-positive metastatic breast cancer who receive treatment in routine care.doi:10.5539/cco.v2n1p17Rudolf Weide...
Some subtypes of aggressive breast cancer, like high-grade tumors called triple-negative tumors, are twice as common among Black women, especially younger Black women, as compared to their White peers. These cancers include: ER+ and HER2/neu-positive subtype ER+ and HER2/neu-negative subtype ...
Kaplan–Meier curves for HER2 status. Survival curves showing cumulative survival differences (end point=breast cancer-specific survival) between patients positive or negative for HER2. P-value represents log-rank testing of the difference in cumulative survival. Full size image Table 2 Subgroup hazard...
Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. We present a retrospective analysis on a cohort of low-grade, node-negative patients showing that human epidermal growth factor receptor 2 (HER2) status si... Tovey,M S.,Brown,... - 《...
Patients with HER2-positive metastatic breast cancer experienced a significant survival benefit when treated with fam-trastuzumab deruxtecan compared with trastuzumab emtansine.
Intratumoral human epidermal growth factor receptor 2 (HER2) heterogeneity has been reported in 16–36% of HER2-positive breast cancer and its clinical impact is under discussion. We examined the biological effects of HER2-heterogeneity on mouse models and analyzed metastatic brains by RNA sequence ...
According to international guidelines, endocrine therapy (ET) is the preferred option for hormone receptor-positive (HR+) HER2-negative (HER2−) metastatic breast cancer. In spite of clear recommendations, these are not strictly followed in daily pract
Advanced inflammatory breast cancer HER2 Case report To the Editor, Inflammatory breast cancer is a special type of breast cancer, and the incidence of HER2-positive subtypes is higher in IBC, accounting for about 35 %–40 %.1,2 This type of breast cancer has a high degree of malignancy an...
This study provides first evidence that MACC1 polymorphisms are associated with clinical outcome for HER2-positive breast cancer patients. Further studies are warranted to validate these findings. 展开 关键词: Breast neoplasms Survival MACC1 Polymorphism Single nucleotide ...